CDCP1-targeted nanoparticles encapsulating phase-shift perfluorohexan for molecular US imaging in vitro
CDCP1-targeted nanoparticles encapsulating phase-shift perfluorohexan for molecular US imaging in vitro
复制标题
CDCP1 靶向纳米粒子封装相移全氟己烷，用于体外分子 US 成像。
DOI：
10.3233/ch-200900
复制
发表时间：
2022-01-01
影响因子：
2.1
通讯作者：
Sun，Ying
中科院分区：
文献类型：
--
作者：
Zhao，Meng;Zhu，Yunkai;Sun，Ying
背景
分子靶向对比增强超声（CEUS）成像是一种潜在的成像策略，可以提高传统超声（US）成像的诊断准确性。美国造影剂通常是微米级的非目标气泡，而纳米级的、含有相移材料的靶向剂因其尺寸和液核以及优异的分子成像效果而吸收更多的吸引力。
方法
采用PLGA12k-mPEG2k-NH2、DSPE-mPEG2k和全氟己烷（PFH）构建了一种具有CUB结构域蛋白1（CDCP1）受体的新型靶向超声造影剂，用于前列腺癌的检测和诊断。体外评估了肿瘤靶向纳米颗粒（CDCP1靶向全氟己烷相变纳米颗粒，抗CDCP1纳米颗粒）作为超声（US）成像造影剂的潜力。此外，还开展了US辅助下的抗CDCP1 NPs的细胞毒性和靶向能力研究。
结果
结果表明，抗CDCP1纳米粒子具有较低的细胞毒性，并且随着抗CDCP1纳米粒子中聚合物浓度的增加，药物的CEUS成像逐渐增强，且成像增强与观察时间的长短相关。此外，还证明抗CDCP1有助于该药物靶向表达CDCP1的细胞，这证明了抗CDCP1 NPs在体外的主动靶向性。
结论
总而言之，利用靶向抗CDCP1纳米粒子增强超声成像的可行性已在体外得到证实，为体内分子超声成像奠定了坚实的基础，抗CDCP1纳米粒子可能具有良好的临床应用前景。
BACKGROUND
Molecular targeted contrast-enhanced ultrasound (CEUS) imaging is a potential imaging strategy to improve the diagnostic accuracy of conventional ultrasound (US) imaging. US contrast agents are usually micrometer-sized and non-target gas bubbles while nano-sized and targeted agents containing phase-shift materials absorb more attractions for their size and the liquid core and excellent molecular imaging effect.
METHODS
PLGA12k-mPEG2k-NH2, DSPE-mPEG2k and perfluorohexan (PFH) were used to construct a new targeted ultrasound contrast agent with CUB domain-containing protein 1 (CDCP1) receptor for the detection and diagnosis of prostate cancer. The potential of tumor-targeted nanoparticles (CDCP1-targeted perfluorohexan-loaded phase-transitional nanoparticles, anti-CDCP1 NPs) as contrast agents for ultrasound (US) imaging was assessed in vitro. Moreover, studies on the cytotoxicity and the targeting ability of anti-CDCP1 NPs assisted by US were carried out.
RESULTS
The results showed that anti-CDCP1 NPs had low cytotoxicity, and with the increasing of polymer concentration in anti-CDCP1 NPs, the CEUS imaging of agent gradually enhanced, and enhanced imaging associated with the length of observing time. Furthermore, it was testified that anti-CDCP1 assisted the agent to target cells expressing CDCP1, which demonstrated the active targeting of anti-CDCP1 NPs in vitro.
CONCLUSION
All in all, the feasibility of using targeted anti-CDCP1 NPs to enhance ultrasound imaging has been demonstrated in vitro, which laid a solid foundation for molecular US imaging in vivo, and anti-CDCP1 NPs might have a great clinical application prospect.